ClinicalTrials.gg
RecruitingNCT06535113Inflamm-AMLUpdated Jun 8, 2026

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

An observational study in Acute Myeloid Leukemia, sponsored by Ciceri Fabio. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Ciceri Fabio · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 67 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.

Planned enrollment
21st of 31
80 · median 202
Started
2025
with 10 others
Observational
31 of 229
11 open now
Primary completion
2026-05
later than 21 of 66 live
Registered
197th of 229
by date

Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 21st largest by planned enrollment of the 31 observational ones that give a count, is one of 11 that started in 2025, is one of 31 observational ones, reaches primary completion later than 21 of the 66 other live ones, and was the 197th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Leukemia, Myeloid, Acute with a site in Italy, or all of them as a file.
02

Study summary

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Read the detailed description

Acute myeloid leukemia (AML) is a highly aggressive and unfavorable malignancy primarily affecting bone marrow (BM) myeloid cells, particularly in older individuals. The standard treatment for fit, intermediate and high-risk patients involves chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, around 60% of patients experience relapse, requiring second-line therapies that offer a reduced likelihood of achieving a permanent cure.

Inflammation significantly influences AML development, progression, leukemic cell behavior, and treatment response. Interactions between leukemic cells and microenvironment promote their growth, survival, and drug resistance. The inflammasome, an intracellular complex crucial for promoting inflammation, triggers the release of the proinflammatory cytokines interleukin (IL)-1beta and IL-18, and induces pyroptosis (inflammatory cell death) in response to inflammatory stimuli. There is growing evidence suggesting a link between the inflammasome and AML, with components of the inflammasome being overexpressed in leukemic cells. The precise mechanisms by which the inflammasome and its activation pathways influence AML still need to be fully understood.

We speculate that excessive inflammasome activity in AML disrupts the balance of cytokine production, leading to chronic inflammation, which interferes with the normal development and function of hematopoietic cells in the BM microenvironment. This heightened inflammasome signature could impact the way patients respond to chemotherapy, potentially altering inflammatory processes, ultimately reducing the efficacy of the treatment. Variations in inflammasome activation among AML patients may explain differences in treatment outcomes, including response rates, hematopoietic recovery, remission duration, and overall survival.

Understanding the molecular mechanisms involved in AML, particularly the role of the inflammasome, could allow a better disease risk stratification and the development of potential targeted therapies and interventions, which could improve treatment outcomes. More specifically, identifying potential therapeutic targets within the inflammasome pathway, may drive to the design of new treatment strategies, precisely aimed at correcting inflammasome dysregulation in AML. From the clinical point of view, these insights could assist healthcare professionals in taking informed decisions in the management of AML patients. By modulating inflammasome activity or targeting specific pathway components, we could develop personalized treatment approaches tailored to individual patient needs, optimizing treatment response and possibly minimizing chemotherapy-related side effects. This personalized approach has the potential to enhance the quality of life for patients, reduce complications, and increase the overall effectiveness of treatments.

During the Study period patients referring to the clinical centers will undergo the standard diagnostic and therapeutic process for their pathology, according to international guidelines. For all the patients that will agree to participate, clinical data and biological samples will be analyzed for the aims of the Study. The retrospective part of the data and material collection must have bio-banked material in compliance with the ethics and regulatory standards for the research purpose.

Due to the Observational nature of the Study, all diagnostic procedures and treatments applied are considered common practice. All treatments comply with the ATC Code L01, the different schemes of treatment could be categorized under an "intensive" or "non intensive" protocol.

Commonly used intensive induction regimens are:

  • 3+7; = daunorubicine 60 mg/m\^2 day 1-3 + cytarabine as continue IV infusion 100/200 mg/m\^2 day 1-7
  • 3+7; + midostaurine 50 mg every 12 hours, day 8-21
  • 3+7; + gemtuzumab ozogamicin 3 mg/m\^2 day 1, 4, 7
  • CPX-351 (daunorubicin 44 mg/cytarabine 100 mg) IV days 1, 3, 5 Commonly used intensive consolidation schemes include intermediate/high dose cytarabine or CPX-351. Midostaurine, gemtuzumab ozogamicin, daunorubicine may be added as per guidelines.

Non intensive induction and consolidation schemes include: azaticidine (75 mg/m\^2) day 1-7 + Venetoclax at variable dose.

For the retrospective collection of samples, the preceding version of ELN guidelines (2017) will be appliedThe main hypothesis of the study is that an excessive inflammasome activity in AML disrupts the balance of cytokine production, leading to a clinically relevant inflammatory state, which interferes with the response to chemotherapy.

In two years, we plan to recruit 80 adult participants with a new diagnosis of AML undergoing first line chemotherapy treatment.

The protocol is a multicenter, national, observational study; indeed, it is based on the Clinical Practice and is aimed at gathering information from the biological samples collected during the diagnosis process and after a first line treatment. The Study will be prospective and retrospective. The total duration of enrolment will be from August 2024 to January 2026, the observation period will be up to 6 months. The information about the treatment and the assessment on disease response/relapse/progression will be collected for stratification and monitoring purpose. Retrospectively, specimens, demographical and clinical information are retrieved from AML patients previously recruited by UO1 will be utilized. Prospectively, new AML patients will be recruited. UO1 recruits AML patients, collects biological samples at diagnosis and after chemotherapy, processes, and biobanks specimens, and conducts functional inflammasome assays, gene expression analysis, and immunophenotyping of AML blasts in peripheral blood and bone marrow. Additionally, immunohistochemistry is performed on bone marrow biopsies. UO2 recruits AML patients, processes and cryobank specimens, and ships samples to UO1. It also produce all diagnostic data for clinical standard of AML blasts in peripheral blood and bone marrow, with immunohistochemistry conducted on bone marrow biopsies.

The biological samples collected for the study include bone marrow, biopsies, and peripheral blood.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Leukemia
  • Chemotherapy
  • inflammation
  • transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted on the population seen at the clinical centers as per common practice. The subjects eligible will be identified during the clinical practice diagnostic process for AML.

The study will involve a total of 80 subjects based on the statistical design for the Study. The Coordinating Unit of the Study will include at least 55 subjects, the Other cooperating Centers will provide the remaining subjects.

The retrospective samples will be identified through Biobanking Records in the pool of samples stocked and we estimate around 25% of the total population included (\~20 subjects).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any gender,
  • Adults (>18 years old),
  • New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
  • Capable of comprehend the study and the consent form,
  • Willing to sign the for the study.

For the retrospective population we will select:

biological samples (BM , BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients (\<18 years old),
  • Patients unable or unwilling to sign the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • acute myeloid leukemia (AML) patients treated in the clinical units

    acute myeloid leukemia (AML) patients treated in the clinical units

    Other: Clinical Practice

Interventions

  • OtherClinical Practice

    All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines. There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.

06

What researchers measure

Primary outcomes

  1. Inflammasome Activity

    The outcome variable is the inflammasome activation in AML blasts (PB e BM)

    Time frame: At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation

Secondary outcomes

  1. Correlation Inflammasome and Therapy

    To evaluate the correlation between inflammasome activity and response to chemotherapy in patients with AML

    Time frame: At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — all Data that underlie results will be published on a peer reviewed paper as for legal requirments

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2026, 14 months.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's 14 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 2, 2024
StartActual
Feb 22, 2025
Primary completionActual
May 11, 2026
CompletionEst.
Aug 31, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535113
Lead sponsor
Ciceri Fabio
Collaborators
Azienda Ospedaliera Bianchi-Melacrino-Morelli
Responsible party
Ciceri Fabio (Prof. MD Director, IRCCS San Raffaele) — Sponsor-investigator
First posted
Aug 2, 2024
Start date
Feb 22, 2025
Primary completion
May 11, 2026
Completion
Aug 31, 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Sara Mastaglio, Haematologist MD
Contact
ciceri.clinicaltrials@hsr.it
+39 0226433917
Vincenzo Mercurio, Ph.D Trial Office Coordinator
Contact
regolatorio.scp@hsr.it
+390226439396

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion